Reinforces Role of AI-Powered Quantitative Coronary Plaque AssessmentMOUNTAIN VIEW, Calif., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for coronary artery disease (CAD), announced the American College of Cardiology (ACC) and the American Heart Association (AHA) published new scientific statements supporting the prognostic value of quantifying coronary plaque and reinforcing the critical role of the coronary computed tomography angiography (CTA) ...

BOSTON--(BUSINESS WIRE)--Novanta Inc. (Nasdaq: NOVT) (the "Company"), a trusted technology partner to medical and advanced technology equipment manufacturers, announced today that Chuck Ravetto, Chief Operating Officer, will be participating at the CJS Securities 26 Annual New Ideas for the New Year Investor Conference on Wednesday, January 14, 2026, which is being held virtually. More information about Novanta is available on the Company's website at www.novanta.com. For additional information, please cont ...

Zacks Premium服务与投资工具 - Zacks Premium是一项研究服务，旨在帮助投资者更明智、更自信地进行投资，提供包括Zacks Rank、Zacks Industry Rank每日更新、Zacks 1 Rank List、股票研究报告和高级股票筛选器在内的多种工具 [1] - 该服务还包含Zacks Style Scores的访问权限 [1] Zacks Style Scores详解 - Zacks Style Scores是一套独特的评级指南，根据价值、增长和动量三种投资类型对股票进行评级，作为Zacks Rank的补充指标，帮助投资者选择在未来30天最有可能跑赢市场的证券 [2] - 每只股票根据其价值、增长和动量特征被赋予A、B、C、D或F的评级，评分越高，股票表现跑赢市场的可能性越大 [3] - Style Scores具体分为四个类别：价值评分、增长评分、动量评分和VGM评分 [3] 各类Style Scores评分标准 - 价值评分：考量市盈率(P/E)、市盈率相对盈利增长比率(PEG)、市销率(Price/Sales)、市现率(Price/Cash Flow)等一系列比率，以找出最具吸引力且被低估的股票 [3] - 增长评分：分析预测及历史盈利、销售额和现金流等特征，以寻找能够持续增长的股票 [4] - 动量评分：利用一周价格变动和盈利预测的月度百分比变化等因素，识别建立股票头寸的良好时机 [5] - VGM评分：综合了价值、增长和动量三种评分，基于其加权组合对每只股票进行评级，帮助投资者找到最具吸引力价值、最佳增长预测和最有望形成动量的公司，也是与Zacks Rank配合使用的最佳指标之一 [6] Zacks Rank与Style Scores的协同应用 - Zacks Rank是一个利用盈利预测修正（即公司盈利预期的变化）来帮助投资者构建成功投资组合的专有股票评级模型 [7] - Zacks Rank 1（强力买入）股票自1988年以来实现了无与伦比的+23.81%的平均年回报率，是标普500指数回报率的两倍多 [8] - 在任何给定日期，有超过200家公司被评为强力买入，另有约600家被评为2（买入），总计超过800只顶级评级股票 [8] - 为最大化回报，应选择同时具有Zacks Rank 1或2以及Style Scores为A或B的股票，如果考虑3（持有）评级的股票，也应确保其具有A或B的评分以保障上行潜力 [9] - 即使股票具有A或B的Style Scores，但如果其Zacks Rank为4（卖出）或5（强力卖出），则盈利预测仍在下降，股价下跌的可能性更大 [10] - 投资者持有的具有1或2 Rank以及A或B Scores的股票越多越好 [10] 案例公司：史赛克 - 史赛克公司总部位于密歇根州卡拉马祖，是医疗技术领域的全球领导者，业务组合涵盖骨科、医疗外科和神经技术 [11] - 2024年，该公司约60%的销售额来自医疗外科和神经技术部门，40%来自骨科部门，约四分之三的收入来自美国，国际销售额（约25%）提供了增长机会 [11] - 该公司在Zacks Rank上被评为3（持有），VGM评分为B [12] - 对于增长型投资者而言，该公司可能是一个首选，其增长评分为B，预计当前财年盈利同比增长11.2% [12] - 对于2025财年，过去60天内10位分析师上调了其盈利预测，Zacks共识预期每股收益上调0.06美元至13.56美元，该公司平均盈利意外为+2.9% [12] - 凭借坚实的Zacks Rank以及顶级的增长和VGM Style Scores，史赛克应列入投资者的关注名单 [13]

We came across a bullish thesis on Baxter International Inc. on Value investing subreddit by Mr-Gambini. In this article, we will summarize the bulls’ thesis on BAX. Baxter International Inc.'s share was trading at $19.29 as of December 17th. BAX’s forward P/E was 8.12 according to Yahoo Finance. Copyright: nimon / 123RF Stock Photo Baxter International (BAX) is a quintessential “boring but essential” medtech company operating in oligopolistic markets for IV solutions, infusion pumps, patient monitoring ...

Key Takeaways TMDX, GMED and HIMS saw strong gains driven by innovation and improved financial performance in 2025.GMED, TMDX and HIMS may face pressure in 2026 amid selective spending and valuation resets.GMED rose 3.8%, TMDX 101.4% and HIMS 32.6% over the past year, outpacing the industry's performances.In 2024 and 2025, the MedTech sector has operated against a backdrop of a global economy marked by slowing growth, moderating inflation and elevated geopolitical uncertainty. Worldwide policy shifts, persi ...

Parnassus Investments, an investment management firm, released its “Parnassus Value Equity Fund” third-quarter 2025 investor letter. A copy of the letter can be downloaded here. The fund focuses on owning a concentrated portfolio of U.S. large-cap stocks. For the third quarter of 2025, the fund reported a net return of 7.46% outperforming its benchmark, the Russell 1000 Value Index, which returned 5.33% for the same period. During the quarter, the portfolio reduced its weight in the IT sector to increase ho ...

Status Quo designation preserves DFU/VLU reimbursement eligibility for 2026, ensuring continued patient access to BioStem technology Coverage for the majority of BioStem’s non-acute revenue, treatment for pressure ulcers, also remains unaffected by CMS LCD updates POMPANO BEACH, Fla., Dec. 18, 2025 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, today ...

Chief Producer: Zhao Haijian Supervising Producer: Shi Shi Editor: Shi Shi Reporter: Gao Jianghong, Li Yinong （原标题：Hainan FTP in Action: China Opens Its Door Wider | SFC Markets and Finance） By Gao Jianghong, Yinong Li, SFC, 21st Century Business Herald On December 18, China's Hainan Free Trade Port officially launched island?wide special customs operations, creating a special customs supervision zone that links overseas markets with the Chinese mainland more smoothly under a "free first line, regulated sec ...

公司财务与资本运作 - Ventripoint Diagnostics Ltd 宣布将通过发行普通股来支付可转换债券的利息 需获得多伦多证券交易所创业板批准 [1] - 公司将发行总计1,145,627股普通股 用于支付总计103,106.29美元的应付利息 这些利息涉及公司在2024年5月10日、6月28日、9月20日以及2025年1月17日、2月7日、3月21日发行的特定未偿还可转换债券 [1] - 可转换债券的年利率为10% 每6个月支付一次利息 此次用于支付利息的股票发行价格被认定为每股0.089美元 股票发行后将面临4个月零1天的限售期 此次发行不会导致公司产生控制权人 [1] 公司业务与技术 - Ventripoint 已成为将人工智能应用于超声心动图领域的行业领导者 [2] - 公司的VMS产品由其专有的基于知识的重建技术驱动 该技术是十年研发的成果 能提供与磁共振成像同等精确的心脏容积测量 这种经济实惠的黄金标准替代方案能让心脏病专家更自信地管理患者 [2] - 公司的VMS+产品用途广泛 可与获得美国、欧洲和加拿大监管市场批准的任何厂商的所有超声系统兼容 [2]

Key Takeaways HOLX said its Genius AI flagged 32% of false-negative mammograms and identified cancer hidden in dense tissue.Researchers reviewed 7,500 3D exams and found HOLX AI detected nearly 90% of cancers seen by radiologists.HOLX noted the study shows AI's potential to boost early detection and strengthen future breast imaging tools.Hologic, Inc. (HOLX) recently announced the latest clinical evidence showing the effectiveness of its Genius AI-based mammography screening technology in improving breast c ...